Drug
Atacicept 75 mg
Atacicept 75 mg is a pharmaceutical drug with 4 clinical trials. Historical success rate of 25.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
25.0%
Based on 1 completed trials
Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
3(75%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
25.0%
1 of 4 finished
Non-Completion Rate
75.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(3)
Detailed Status
Terminated3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed125%
terminated375%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
Efficacy and Safety of Atacicept in IgA Nephropathy
NCT02808429
terminatedphase_2
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
NCT02070978
terminatedphase_2
Atacicept in Multiple Sclerosis Extension Study, Phase II
NCT00853762
completedphase_2
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
NCT00624338
Clinical Trials (4)
Showing 4 of 4 trials
NCT02808429Phase 2
Efficacy and Safety of Atacicept in IgA Nephropathy
NCT02070978Phase 2
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
NCT00853762Phase 2
Atacicept in Multiple Sclerosis Extension Study, Phase II
NCT00624338Phase 2
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4